CJC-1295 vs Ipamorelin
Both are studied along the growth-hormone axis and sold together as our CJC-1295 + Ipamorelin Blend — but they act on two different receptors entirely, which is exactly why they're often researched as a pair.
At a Glance
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Category | GHRH & Growth Hormone | GHRH & Growth Hormone |
| Molecular class | Modified GHRH(1-29) analog (Drug Affinity Complex technology) | Pentapeptide (5 amino acids) |
| Discovery timeline | Mid-2000s, ConjuChem (Canada) | Developed at Novo Nordisk, first published 1998 |
| Target receptor | GHRH receptor | Ghrelin receptor (GHS-R) |
| Primary mechanism studied | Extending and amplifying the body's natural GHRH pulse | Selective growth-hormone release with minimal cortisol/prolactin effect |
| Sold as a blend | Yes — see CJC-1295 + Ipamorelin Blend | Yes — see CJC-1295 + Ipamorelin Blend |
How They Differ
CJC-1295 was developed by the Canadian biotech ConjuChem in the mid-2000s using “Drug Affinity Complex” technology, which binds the molecule to serum albumin in the bloodstream to extend GHRH's natural half-life from minutes to several days. It works through the GHRH receptor — the same pathway the body's own growth-hormone-releasing hormone uses.
Ipamorelin takes a different route entirely. Developed at Novo Nordisk and first published in 1998, it works through the ghrelin receptor — a separate growth-hormone-release pathway — and was specifically engineered for receptor selectivity, avoiding the cortisol, ACTH, and prolactin spikes seen with earlier growth-hormone secretagogues. See its full discovery history.
Why They're Often Studied Together
Because CJC-1295 and Ipamorelin act on two distinct receptors within the same growth-hormone axis — the GHRH receptor and the ghrelin receptor, respectively — combining them is studied for potential dual-pathway effects on growth hormone release, which is the rationale behind our CJC-1295 + Ipamorelin Blend.
CJC-1295 vs Ipamorelin questions
Do CJC-1295 and Ipamorelin work the same way?
No. CJC-1295 acts on the GHRH receptor, extending the body's natural growth-hormone-releasing signal. Ipamorelin acts on a separate pathway, the ghrelin receptor, with a selectivity profile that avoids off-target hormonal effects. They're studied together specifically because they engage different receptors in the same axis.
Does this comparison mean CJC-1295 and Ipamorelin are approved for a particular use?
No. This page compares CJC-1295 and Ipamorelin for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.